May 31, 2019
Generic drug maker Heritage Pharmaceuticals, Inc.
has entered into a deferred prosecution agreement for criminal antitrust charges, admitting that it conspired to fix prices, rig bids, and allocate customers for the diabetes drug glyburide. Heritage will pay a $225,000 criminal penalty and has agreed to cooperate in ongoing antitrust investigations. In addition, Heritage will pay $7.1 million
to resolve allegations under the False Claims Act that the company paid and received unlawful remuneration under the Anti-Kickback Statute through its arrangements with other generic drug makers regarding prices, supply, and allocation of customers for drugs including glyburide, hydralazine, and theophylline. DOJ
; USAO ED Pa